Atractylodin alleviates cancer anorexia-cachexia syndrome by regulating NPY through hypothalamic Sirt1/AMPK axis-induced autophagy

Bai, Yu; Zhao, Yanhua; TENG, SHICHAO; Ni, Yongcheng; Xu, Shunjuan; Wang, Xiang; Zhang, Jing; Xu, Xiaofeng; Fang, Yuan; Shi, Jun; Zhang, Biao

doi:10.1016/j.bbrc.2022.08.011

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another preclinical study, Yu and others 11 tested atractylodin, an agent that purportedly blocks inflammatory cytokines, in mice. These investigators reported how this agent appears to promote the expression of neuropeptide y and also appeared to increase appetite.…”

Section: Mechanismsmentioning

confidence: 99%

Loss of appetite in patients with cancer: an update on characterization, mechanisms, and palliative therapeutics

Haemmerle¹,

Jatoi

2023

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of review Over the past year, loss of appetite in patients with cancer has continued to be an area of active investigation. This review provides an update of recently published findings. Recent findings Despite the emergence of new cancer therapeutic agents, this symptom of loss of appetite continues to trouble patients, and it continues to be associated with poor survival. Recent preclinical research promises to lead to newer approaches and newer, more effective palliative agents. Recent clinical research shows that agents such as olanzapine, anamorelin, and cannabis either do or might palliate this symptom. Summary Loss of appetite in patients with cancer remains an important area of clinical and research focus. Recent published data provide greater clarity with respect to how to palliate this symptom. Today, although clinicians have more options to palliate cancer-associated loss of appetite than ever before, questions remain unanswered about how to palliate this symptom optimally and how to improve the quality of life of patients who suffer from it.

show abstract

Section: Mechanismsmentioning

confidence: 99%

Loss of appetite in patients with cancer: an update on characterization, mechanisms, and palliative therapeutics

Haemmerle¹,

Jatoi

2023

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

“…SIRT1 has recently been given increasing attention in muscle function [ 25 ], muscle physiology [ 26 , 27 ], balancing muscle cell differentiation [ 28 ], and proliferation [ 29 , 30 ], especially in cancer cachexia-induced muscle atrophy [ 31 , 32 ]. SIRT1 plays an essential role in inhibiting the production of inflammatory factors such as IL-6 and the NF-κB signaling pathway in colon and pancreatic cancer [ 31 , 32 , 33 ]. Furthermore, several studies have found that the content of SIRT1 decreased significantly in the course of cancer cachexia [ 31 , 34 ].…”

Section: Introductionmentioning

confidence: 99%

Ursolic Acid Alleviates Cancer Cachexia and Prevents Muscle Wasting via Activating SIRT1

Tao

Ouyang

Liao

et al. 2023

Cancers

View full text Add to dashboard Cite

Skeletal muscle wasting is the most remarkable phenotypic feature of cancer cachexia that increases the risk of morbidity and mortality. However, there are currently no effective drugs against cancer cachexia. Ursolic acid (UA) is a lipophilic pentacyclic triterpene that has been reported to alleviate muscle atrophy and reduce muscle decomposition in some disease models. This study aimed to explore the role and mechanisms of UA treatment in cancer cachexia. We found that UA attenuated Lewis lung carcinoma (LLC)-conditioned medium-induced C2C12 myotube atrophy and muscle wasting of LLC tumor-bearing mice. Moreover, UA dose-dependently activated SIRT1 and downregulated MuRF1 and Atrogin-1. Molecular docking results revealed a good binding effect on UA and SIRT1 protein. UA rescued vital features wasting without impacting tumor growth, suppressed the elevated spleen weight, and downregulated serum concentrations of inflammatory cytokines in vivo. The above phenomena can be attenuated by Ex-527, an inhibitor of SIRT1. Furthermore, UA remained protective against cancer cachexia in the advanced stage of tumor growth. The results revealed that UA exerts an anti-cachexia effect via activating SIRT1, thereby downregulating the phosphorylation levels of NF-κB and STAT3. UA might be a potential drug against cancer cachexia.

show abstract

Atractylodin alleviates cancer anorexia-cachexia syndrome by regulating NPY through hypothalamic Sirt1/AMPK axis-induced autophagy

Cited by 2 publications

References 23 publications

Loss of appetite in patients with cancer: an update on characterization, mechanisms, and palliative therapeutics

Loss of appetite in patients with cancer: an update on characterization, mechanisms, and palliative therapeutics

Ursolic Acid Alleviates Cancer Cachexia and Prevents Muscle Wasting via Activating SIRT1

Contact Info

Product

Resources

About